NCT05914714

Ruxolitinib as GVHD Prophylaxis in AA Patients

Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Allogeneic Stem Cell Transplantation in Aplastic Anemia Patients

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 46 (estimated)
• Sponsor: Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
• Sex: All
• Age: 14 Years
• Healthy volunteers: Not accepted

Summary

Our study aimed to determine the prophylactic value of ruxolitinib for aGVHD in HSCT recipients of AA.Ruxolitinib was initiated at the beginning of conditioning regimen at 5 twice daily until 3 months post-transplantation. The cumulative incidence of aGVHD within 6 months after HSCT will be the primary observation item.

Conditions

• The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA

Interventions

Type	Name	Description
DRUG	Ruxolitinib 5 MG BID Oral Tablet	ruxolitinib 5mgBID will be administrated at the beginning of the conditioning regimen until 3 months post-transplantation.

Timeline

• Start date: 2023-07-01
• Primary completion: 2025-05-01
• Completion: 2025-05-01
• First posted: 2023-06-22
• Last updated: 2023-06-22

Regulatory

• FDA-regulated drug study